Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2007

Chang John Wen-Cheng, Chou Chun-Liang, Huang Shiu-Feng, Wang Hung-Ming, Hsieh Jia-Juan, Hsu Todd, Cheung Yun-Chung

Abstract excerpt

PURPOSE: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. PATIENT AND METHODS: Lung specimen was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Lung Neoplasms

Share to Quinazolines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 17618013
DOI: 10.1016/j.lungcan.2007.05.018

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17618013-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.PMID 17618013Read ↗

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.Semantic proximity Read ↗

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Semantic proximity Read ↗

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.Semantic proximity Read ↗

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.Semantic proximity Read ↗

Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Semantic proximity Read ↗

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case reportSemantic proximity Read ↗

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.